Sophia Genetics on Tuesday reported $11.7 million in revenues for the second quarter of 2022, an increase of 15% compared to $10.2 million in Q2 2021.
The firm said that its year-over-year revenue growth on a constant currency basis, excluding COVID-19-related revenues, was 36%.
Platform analysis volumes increased to 65,889 analyses for the second quarter of 2022, compared to 62,837 analyses for the second quarter of 2021.
For the quarter ended June 30, the firm posted a net loss of $24.7 million, or $.39 per share, compared to a net loss of $18.4 million, or $.38 per share, in Q2 2021.
At the end of the quarter, the firm had cash and cash equivalents of $178.9 million.
Looking ahead, the firm -- with headquarters in Lausanne, Switzerland and Boston -- reiterated its expectations of constant currency revenue growth of 30% to 35% for full-year 2022. Sophia Genetics expects full-year 2022 revenues to be between $47 million and $49.5 million.
Sophia Genetics shares were down more than 3% to $4.90 in Tuesday morning trading on the Nasdaq.
